You Position: Home > Paper

Latest progress in the development of anti-2019-nCoV therapeutic drugs

( views:63, downloads:6 )
Author:
No author available
Journal Title:
Chinese Journal of Clinical Infectious Diseases
Issue:
2
DOI:
10.3760/cma.j.issn.1674-2397.2022.02.003
Key Word:
冠状病毒;新型冠状病毒;抗病毒药物;单克隆中和抗体;Coronavirus;2019-nCoV;Antiviral drugs;Monoclonal neutralizing antibody

Abstract: In recent years, great progress has been made in small molecule therapeutic drugs and monoclonal neutralizing antibody preparations against 2019-nCoV. At least 5 oral drugs (Monupavir, AT-527, Proclutamide, Paxlovid and S-217622) and 2 monoclonal antibodies (Ambavirumab/Romisevirumab combination and Sotrovimab) have completed phase Ⅲ clinical trials exhibiting excellent antiviral effects. This article reviews the research progress of these 7 drugs to provide reference for clinical application.

  • This article has no references!
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn